They included alpha skeletal muscle actin (ACTA1), gamma-enteric smooth muscle actin (ACTG2), ADAMTS13, hepatocyte growth factor activator (HGFAC), neprilysin, and tenascin C. Further effort is required to validate these biomarkers and discover novel biomarkers in the liquid biopsies from a larger cohort of osteosarcoma patients in order to improve plasma-based screening and diagnosis in patients. This evidence concerns the gene ACTA1 and osteosarcoma.